Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Submitted by
admin
on June 2, 2017 - 11:16am
Source:
Endpoints
News Tags:
Bristol-Myers
Seattle Genetics
Opdivo
Adcetris
Hodgkin's lymphoma
Headline:
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Do Not Allow Advertisers to Use My Personal information
